Nov 04, 2021 / 01:15PM GMT
Presentation (London-Based Investors)
Nov 04, 2021 / 01:15PM GMT
=====================
Corporate Participants
=====================
* Camilla Sylvest
Novo Nordisk A/S - Executive VP, Head of Commercial Strategy & Corporate Affairs and Member of the Management Board
* Karsten Munk Knudsen
Novo Nordisk A/S - Executive VP, CFO & Member of the Management Board
* Martin Holst Lange
Novo Nordisk A/S - Executive VP, Head of Development & Member of the Management Board
=====================
Conference Call Participants
=====================
* Jo Walton
Crédit Suisse AG, Research Division - MD
* Keyur Parekh
Goldman Sachs Group, Inc., Research Division - Equity Analyst
* Michael Leuchten
UBS Investment Bank, Research Division - Co-Head of Pharmaceuticals Research of Equity Research
* Peter Verdult
Citigroup Inc. Exchange Research - Research Analyst
* Peter James Welford
Jefferies LLC, Research Division - Senior Equity Analyst & European Pharmaceuticals
Novo Nordisk AS
(NYSE:NVO)
$
48.89
-0.75 (-1.51%)
Market Cap: 216.33 Bil
Enterprise Value: 235.38 Bil
PE Ratio: 11.47
PB Ratio: 7.04
GF Score: 71/100 Q3 2021 Novo Nordisk A/S Earnings Presentation (London-Based Investors) Transcript
Nov 04, 2021 / 01:15PM GMT
Release Date Price:
$57.93
(+0.25%)
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers